Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) was upgraded by stock analysts at StockNews.com to a "sell" rating in a research report issued to clients and investors on Monday.
Separately, Needham & Company LLC reaffirmed a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Thursday.
Read Our Latest Analysis on LXRX
Lexicon Pharmaceuticals Price Performance
NASDAQ:LXRX traded down $0.10 during midday trading on Monday, hitting $1.87. The company had a trading volume of 3,490,098 shares, compared to its average volume of 4,476,207. The company has a market capitalization of $460.47 million, a PE ratio of -2.34 and a beta of 1.27. The company has a quick ratio of 5.58, a current ratio of 5.60 and a debt-to-equity ratio of 1.07. Lexicon Pharmaceuticals has a 52-week low of $0.92 and a 52-week high of $3.79. The stock's fifty day moving average price is $2.41 and its 200-day moving average price is $1.69.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.68 million. Lexicon Pharmaceuticals had a negative return on equity of 138.54% and a negative net margin of 14,573.20%. As a group, research analysts expect that Lexicon Pharmaceuticals will post -0.71 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of LXRX. Cantor Fitzgerald L. P. purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter worth about $25,000. Bank of Montreal Can bought a new stake in Lexicon Pharmaceuticals during the 1st quarter valued at approximately $26,000. TIAA Trust National Association purchased a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter worth approximately $29,000. Kestra Advisory Services LLC bought a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter worth approximately $33,000. Finally, Principal Securities Inc. purchased a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at approximately $33,000. Institutional investors own 74.70% of the company's stock.
About Lexicon Pharmaceuticals
(
Get Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
